You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Stage IV NSCLC

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Stage IV Trial in New York (Pembrolizumab, Radiation, Chemotherapy)

Recruiting
  • NSCLC Stage IV
  • New York, New York
    NYU Langone Health
Jan 11, 2023

Non Small Cell Lung Cancer Trial in Ostrava (Chemotherapy, Radiotherapy (RT) + Stereotactic Body Ratio Therapy (SBRT),

Recruiting
  • Non Small Cell Lung Cancer
  • Chemotherapy
  • +2 more
  • Ostrava, Moravian-Silesian Region, Czechia
    University Hospital Ostrava
Dec 19, 2022

Non Small Cell Lung Cancer Metastatic Trial (Pembrolizumab, Pembrolizumab biosimilar)

Not yet recruiting
  • Non Small Cell Lung Cancer Metastatic
  • (no location specified)
Dec 19, 2022

Aspirin in Combination With Trametinib and Dabrafenib

Not yet recruiting
  • NSCLC
  • +4 more
  • Combind asprin with Trametinib and Dabrafenib
  • (no location specified)
Aug 4, 2023

Stage IV NSCLC Trial in Houston (Poly ICLC, IVIG)

Not yet recruiting
  • Stage IV NSCLC
  • Houston, Texas
    Michael E. DeBakey VA Medical Center, Houston, TX
Sep 28, 2023

Prophylactic Cranial Irradiation, Cumulative Incidence of Brain Metastases Trial in Guiyang (Prophylactic Cranial Irradiation

Recruiting
  • Prophylactic Cranial Irradiation, Cumulative Incidence of Brain Metastases
  • Prophylactic Cranial Irradiation for experiment arm
  • Guiyang, Guizhou, China
    Guizhou Cancer Hospital
Aug 23, 2023

Lung Cancer, NSCLC Trial in Tampa (Vorinostat, Pembrolizumab)

Active, not recruiting
  • Lung Cancer
  • Non-small Cell Lung Cancer
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Nov 10, 2022

Stage IV NSCLC Trial in Wuhan (SBRT+Osimertinib, Osimertinib 80 MG)

Not yet recruiting
  • Stage IV Non-small Cell Lung Cancer
  • SBRT+Osimertinib
  • Osimertinib 80 MG
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated to Tongji Medical College of Huazhong
Oct 13, 2022

NSCLC Stage IV Trial in Taipei (therapeutic thoracic surgery, Afatinib)

Recruiting
  • NSCLC Stage IV
  • Taipei, Taiwan
  • +1 more
Mar 8, 2022

Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer Trial in United States (BMF-219)

Recruiting
  • Non Small Cell Lung Cancer
  • +16 more
  • Goodyear, Arizona
  • +10 more
Jan 24, 2023

NSCLC Without Mutation in Epidermal Growth Factor Receptor (Disorder) Trial (tereotactic body radiotherapy)

Not yet recruiting
  • Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)
  • tereotactic body radiotherapy
  • (no location specified)
Dec 1, 2023

Non-Small Cell Carcinoma of Lung, TNM Stage 4 Trial in Philadelphia (Arm A, Arm B)

Recruiting
  • Non-Small Cell Carcinoma of Lung, TNM Stage 4
  • Arm A
  • Arm B
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Feb 8, 2022

Stage IIIB(N2) NSCLC, Stage IIA NSCLC, Stage IIB NSCLC Trial in Beijing (Pembrolizumab 200 mg IV infusion)

Not yet recruiting
  • Stage IIIB(N2) Non-small Cell Lung Cancer
  • +3 more
  • Pembrolizumab 200 mg IV infusion
  • Beijing, Beijing, China
    Peking University
May 30, 2023

NSCLC Stage IV, ALK Fusion Protein Expression Trial (Peptide vaccine)

Not yet recruiting
  • NSCLC Stage IV
  • ALK Fusion Protein Expression
  • Peptide vaccine
  • (no location specified)
Jul 21, 2023

NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV Trial in Worldwide (Dacomitinib)

Active, not recruiting
  • NSCLC Stage IIIB
  • +4 more
  • Hong Kong, Hong Kong
  • +8 more
Jan 10, 2023

NSCLC Stage IV, NSCLC Stage IIIB, NSCLC Stage IIIC Trial in China (Cadonilimab, Anlotinib, Docetaxel)

Recruiting
  • NSCLC Stage IV
  • +2 more
  • Hefei, Anhui, China
  • +4 more
Apr 15, 2023

Clinical Implications for NSCLC Patients With Rare Mutations

Recruiting
  • NSCLC
  • +2 more
    • Shanghai, Shanghai, China
    • +1 more
    Jan 18, 2023

    High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

    Suspended
    • NSCLC Stage IV
    • NSCLC, Stage IIIC
    • Primary Immune Response (PIR) test by Biodesix, Inc.
    • San Carlos, California
    • +1 more
    Jan 26, 2023

    Stage IV NSCLC Trial in Dallas (Stereotactic Body Radiation Therapy, Maintenance chemo)

    Completed
    • Stage IV Non-Small Cell Lung Cancer
    • Stereotactic Body Radiation Therapy
    • Maintenance chemotherapy
    • Dallas, Texas
      UT Southwestern Medical Center
    Jun 30, 2022

    NSCLC Trial in Worldwide (BMS-986315, Nivolumab, Pemetrexed)

    Not yet recruiting
    • NSCLC
    • Boise, Idaho
    • +12 more
    Oct 17, 2023

    China With Non-Small-Cell Lung Cancer That is Unable to be

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
      • (no location specified)
      May 16, 2023

      Double-dose Furmonertinib in Treatment of Slow

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • +3 more
      • (no location specified)
      Oct 31, 2023

      NSCLC (NSCLC), Stage IV Trial in Switzerland (Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy),

      Not yet recruiting
      • Non-small Cell Lung Cancer (NSCLC)
      • Stage IV
      • Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)
      • +2 more
      • Aarau, Switzerland
      • +7 more
      Oct 27, 2023

      NSCLC Trial in Rozzano (Pemetrexed/Carboplatin, Gemcitabine)

      Terminated
      • NSCLC
      • Rozzano, Milan, Italy
        Istituto Clinco Humanitas
      Sep 8, 2022

      Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in

      Not yet recruiting
      • Metastatic Lung Non-Small Cell Carcinoma
      • +2 more
      • Cetuximab
      • +2 more
      • Sacramento, California
        University of California Davis Comprehensive Cancer Center
      Oct 2, 2023